Biotechnology | North America COVID-19: Increasing ConvictionMultiple Vaccine Candidates WillHave Pivotal Data Before YE20 While a pre-election result is possible, we see early-to-mid November as our base case for PhIII data. Pfizer/BioNTech and Moderna appear slightly ahead of AstraZeneca for US PhIII data, though we note many details on the PhIIIs have not been disclosed which could impact our projected…

This content is for Premium Membership and Contributor Membership members only.
Login Join Now

©2024 Finom Group | Website by: Ocala Website Designs LLC

Log in with your credentials


Forgot your details?

Create Account